James Healy - 25 Sep 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Sep 2024, 16:22:43 UTC
Prior SEC filing
30 Jul 2024
Next SEC filing
29 Oct 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

James Healy filed Form 4 for BioAge Labs, Inc. (BIOA) on 27 Sep 2024.

Key facts

  • This page summarizes James Healy's Form 4 filing for BioAge Labs, Inc. (BIOA).
  • 8 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 27 Sep 2024, 16:22.

Change

  • Previous filing in this sequence was filed on 30 Jul 2024.
  • Current net transaction value: +$11,999,970.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+1,638,236
Change %
Price
Shares after
1,638,236
Date
27 Sep 2024
Ownership
Sofinnova Venture Partners XI, L.P.
Footnotes
F1, F2, F3
BIOA transaction

Common Stock

Purchase

Transaction value
$10,599,984
Shares
+588,888
Change %
+36%
Price
$18.00
Shares after
2,227,124
Date
27 Sep 2024
Ownership
Sofinnova Venture Partners XI, L.P.
Footnotes
F2, F3, F4
BIOA transaction

Common Stock

Purchase

Transaction value
$200,034
Shares
+11,113
Change %
Price
$18.00
Shares after
11,113
Date
27 Sep 2024
Ownership
Sofinnova Synergy Master Fund LP
Footnotes
F3, F5
BIOA transaction

Common Stock

Purchase

Transaction value
$330,354
Shares
+18,353
Change %
Price
$18.00
Shares after
18,353
Date
27 Sep 2024
Ownership
CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP
Footnotes
F3, F6
BIOA transaction

Common Stock

Purchase

Transaction value
$392,652
Shares
+21,814
Change %
Price
$18.00
Shares after
21,814
Date
27 Sep 2024
Ownership
Crestline Summit Master, SPC - PEAK SP
Footnotes
F3, F7
BIOA transaction

Common Stock

Purchase

Transaction value
$476,946
Shares
+26,497
Change %
Price
$18.00
Shares after
26,497
Date
27 Sep 2024
Ownership
CRESTLINE SUMMIT PINNACLE MASTER, L.P.
Footnotes
F3, F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+15,000
Change %
Price
$0.000000
Shares after
15,000
Date
25 Sep 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,000
Exercise price
$18.00
Footnotes
F9
BIOA transaction Derivative

Series D Preferred Stock

Conversion of derivative security

Transaction value
Shares
-7,310,796
Change %
-100%
Price
Shares after
0
Date
27 Sep 2024
Ownership
Sofinnova Venture Partners XI, L.P.
Underlying class
Common Stock
Underlying amount
1,638,236
Exercise price
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date.

Footnote F2

These shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The reporting person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI.

Footnote F3

The reporting person disclaims beneficial ownership of the securities directly held by each of: (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any.

Footnote F4

Represents shares purchased from the Issuer in a private placement transaction.

Footnote F5

These shares are directly held by Sofinnova Synergy Master Fund LP ("Synergy Fund"). Sofinnova Synergy GP, LLC ("Synergy Fund GP") is the general partner of Synergy Fund. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Synergy Fund.

Footnote F6

These shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP ("APEX SP"). Synergy Fund GP is the general partner of APEX SP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by APEX SP.

Footnote F7

The shares are directly held by Crestline Summit Master, SPC - PEAK SP ("PEAK SP"). Synergy Fund GP is the general partner of PEAK SP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by PEAK SP.

Footnote F8

The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. ("Pinnacle LP"). Synergy Fund GP is the general partner of Pinnacle LP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Pinnacle LP.

Footnote F9

The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .